Mandate

Bravida listed on Nasdaq Stockholm

October 22, 2015

Bravida Holding AB (publ) has on 16 October 2015 been admitted to trading on Nasdaq Stockholm. The price in the offering was set at SEK 40 per share, corresponding to a market value of all shares issued by Bravida of SEK 8.1 billion. The offer, which consisted of an offer to the general public in Sweden and an international offer to institutional investors, comprised in total 40.5 percent of the Bravida shares offered by Bravissima Holding AB, Bravida´s principal owner, which is indirectly controlled by certain investment funds advised by Bain Capital, LLC and affiliated parties. The total value of the offering amounts to SEK 3.2 billion, assuming that the over-allotment option is exercised in full.

Bravida is a leading provider of multi-technical services within electricity, heating and plumbing as well as ventilation and air conditioning in the Nordic region. With 237 branches across 140 locations, Bravida offers installation and services solutions throughout the Nordic region with strong local presence. For the year ended 31 December 2014, Bravida recorded net sales of SEK 12 billion.

Bravida and Bravissima Holding AB were advised by Vinge in connection with the listing and Vinge’s team mainly consisted of Charlotte Levin, Christina Kokko, Louise Brorsson Salomon, Nicolina Kindblom, Rikard Lindahl, Nils Fredrik Dehlin, Emelie Klefbeck, Filip Öhrner, Linn Adelwald and Samra Baytar. Further, Odile Fallenius, Maria Schultzberg and Tora Hansjons have assisted with tax related matters.

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026